Sorrento Rallies On EUA Filing For Rapid COVID-19 Antibody Test Kit

Sorrento Therapeutics Inc SRNE shares were headed higher Thursday following an announcement concerning its antibody test kit for SARS-CoV-2, the virus that causes COVID-19.

What Happened: Sorrento said it has filed for an Emergency Use Authorization for its in vitro diagnostic test kit, COVI-TRACK, for independent detection of IgG and IgM antibodies in the blood of patients exposed to the virus.

The antibody test is capable of yielding results in 8 minutes or less, according to the company. The test confirms the assay validity by developing three clear lines. 

Upon validation testing, the test demonstrated a specificity greater than 97% and diagnostic sensitivity of greater than 94%, Sorrento said. 

What's Next: If the FDA issues an EUA, the company said the COVI-TRACK test will be available for distribution to clinical testing sites nationwide. The company also said it has secured manufacturing capacity to produce up to 5 million test kits per month.

COVI-TRACK appears to have highly competitive attributes, H.C. Wainwright analyst Raghuram Selvaraju said in a note, citing rapid generation of results and readily interpretable results. The test also has performance metrics above the thresholds set by the FDA, the analyst said. 

SRNE Price Action: At last check, Sorrento shares were advancing 4.96% to $4.76.

Related Links:

Sorrento Therapeutics Analyst Says Coronavirus Antibody Cocktail One Of Few Non-Vaccine Options

Sorrento Therapeutics Has $4B Coronavirus Opportunity, Analyst Says

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst ColorBiotechNewsHealth CareAnalyst RatingsGeneralCoronavirusCovid-19H.C. WainwrightRaghuram Selvaraju
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!